SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

GSK is moving out of its 635K SF footprint at 14200 Shady Grove Road, where it is the sole tenant, just before its lease ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

When drug companies manipulate the system to increase profits, patients suffer. Arizona Attorney General Kris Mayes is right to take GlaxoSmithKline to court over its decision to discontinue Flovent, ...

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...